PremiumPress ReleasesSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
PremiumPress ReleasesSenti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting